{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:39:58Z","timestamp":1790505598790,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejca.2021.04.015","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T17:24:57Z","timestamp":1622309097000},"page":"26-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG \u201cANITA\u201d"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"Patrick","family":"Sch\u00f6ffski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Toulmonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2788-9159","authenticated-orcid":false,"given":"Anna","family":"Estival","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8961-9787","authenticated-orcid":false,"given":"Gloria","family":"Marquina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Dudzisz-\u015aled\u017a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Brahmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5806-9399","authenticated-orcid":false,"given":"Vasilios","family":"Karavasilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1629-4715","authenticated-orcid":false,"given":"Jacco","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9726-144X","authenticated-orcid":false,"given":"Agnieszka","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cousin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Dom\u00e8nech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith V.M.G.","family":"Bov\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Charon-Barra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Marreaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Liti\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1485-1960","authenticated-orcid":false,"given":"Laura","family":"De Meulemeester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Olungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.04.015_bib1","unstructured":"National Comprehensive Cancer Network. NCCN guidelines 1.2021 soft tissue sarcoma. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma_blocks.pdf\u2019."},{"key":"10.1016\/j.ejca.2021.04.015_bib2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ejca.2012.09.011","article-title":"Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project","volume":"49","author":"Stiller","year":"2013","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.04.015_bib3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/1758834017712963","article-title":"Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations","volume":"9","author":"In","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2021.04.015_bib4","doi-asserted-by":"crossref","first-page":"iv51","DOI":"10.1093\/annonc\/mdy096","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.04.015_bib5","article-title":"Soft tissue and bone tumours","volume":"vol. 3","year":"2020"},{"key":"10.1016\/j.ejca.2021.04.015_bib6","unstructured":"National Cancer Institute, Surveillance, epidemiology, and end results (SEER). Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/soft.html. Last accessed 06 January 2021."},{"key":"10.1016\/j.ejca.2021.04.015_bib7","article-title":"A nomogram to predict metastasis of soft tissue sarcoma of the extremities","volume":"99","author":"Li","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.ejca.2021.04.015_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2017.10.020","article-title":"EJC's biennial report on metastatic soft tissue sarcoma: state of the art and future perspectives","volume":"88","author":"Vos","year":"2018","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.04.015_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.04.015_bib10","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/S0959-8049(02)00491-4","article-title":"Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients","volume":"38","author":"van Oosterom","year":"2002","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.04.015_bib11","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.015_bib12","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.015_bib13","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.04.015_bib14","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.04.015_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000328795","article-title":"High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients","volume":"80","author":"Lee","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2021.04.015_bib16","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ejca.2021.04.015_bib17","first-page":"267","article-title":"The contribution of angiogenesis to the process of metastasis","volume":"21","author":"Bielenberg","year":"2015","journal-title":"Canc J"},{"key":"10.1016\/j.ejca.2021.04.015_bib18","first-page":"3591","article-title":"Expression of vascular endothelial growth factor and its receptor, KDR\/Flk-1, in soft tissue sarcomas","volume":"25","author":"Pakos","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2021.04.015_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdh309","article-title":"Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma","volume":"15","author":"Yoon","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.04.015_bib20","first-page":"560","article-title":"Cell proliferation in human soft tissue tumors correlates with platelet-derived growth factor B chain expression: an immunohistochemical and in situ hybridization study","volume":"54","author":"Wang","year":"1994","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2021.04.015_bib21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/1078-0432.CCR-09-0694","article-title":"Phase I study of the angiogenesis inhibitor nintedanib (BIBF1120) in patients with advanced solid tumours","volume":"16","author":"Mross","year":"2010","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.04.015_bib22","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/annonc\/mdq618","article-title":"A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer","volume":"22","author":"Reck","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.04.015_bib23","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2011.38.5732","article-title":"Design issues in randomized phase II\/III trials","volume":"30","author":"Korn","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.015_bib24","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2006.09.7717","article-title":"Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study","volume":"25","author":"Lorigan","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.015_bib25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","article-title":"Progression-free rate as the principal end-point for phase II trials in soft tissue sarcomas","volume":"38","author":"Van Glabbeke","year":"2002","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.04.015_bib26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2021.04.015_bib27","unstructured":"Vargatef (nintedanib) Summary of Product Characteristics. Boehringer Ingelheim International, Ingelheim am Rhein, Germany. Renewed: 26\/08\/2019. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vargatef-epar-product-information_en.pdf."},{"key":"10.1016\/j.ejca.2021.04.015_bib28","unstructured":"Votrient (pazopanib) Prescribing Information.Novartis Pharmaceuticals Corp; East Hanover, NJ. Revised: 8\/2020. Available at: https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/votrient.pdf."},{"key":"10.1016\/j.ejca.2021.04.015_bib29","first-page":"1324","article-title":"Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy","volume":"9","author":"Sloan","year":"2008","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1016\/j.ejca.2021.04.015_bib30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/PAP.0b013e318253462f","article-title":"New therapeutic targets in soft tissue sarcoma","volume":"19","author":"Demicco","year":"2012","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.ejca.2021.04.015_bib31","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/ijms20010170","article-title":"Therapeutic targets for bone and soft-tissue sarcomas","volume":"20","author":"Miwa","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2021.04.015_bib32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2215\/CJN.03530412","article-title":"Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center","volume":"8","author":"Salahudeen","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejca.2021.04.015_bib33","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/ckj\/sfz183","article-title":"Ifosfamide nephrotoxicity in adult patients","volume":"13","author":"Ensergueix","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ejca.2021.04.015_bib34","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jfma.2015.07.016","article-title":"Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: a retrospective analysis","volume":"115","author":"Lo","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.ejca.2021.04.015_bib35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.coc.0000158439.02724.5a","article-title":"Evaluating risk factors for the development of ifosfamide encephalopathy","volume":"28","author":"David","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.015_bib36","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/jcpt.12823","article-title":"Ifosfamide-induced encephalopathy: brand-name (HOLOXAN\u00ae) vs generic formulation (IFOSFAMIDE EG\u00ae)","volume":"44","author":"Chambord","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ejca.2021.04.015_bib37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2009.09.022","volume":"46","author":"Sleijfer","year":"2010","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.04.015_bib38","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/0284186X.2018.1449248","article-title":"Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database","volume":"57","author":"Sleijfer","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2021.04.015_bib39","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1634\/theoncologist.10-10-833","article-title":"Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care","volume":"10","author":"Sleijfer","year":"2005","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2021.04.015_bib40","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","article-title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial","volume":"18","author":"Tap","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.04.015_bib41","doi-asserted-by":"crossref","first-page":"vi483","DOI":"10.1093\/annonc\/mdw388.01","article-title":"Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): study TH-CR-406\/SARC021","volume":"27","author":"Tap","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.04.015_bib42","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2016.67.6684","article-title":"PICASSO III: a Phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma","volume":"34","author":"Ryan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.015_bib43","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2020.1707","article-title":"Effect of doxorubicin\u00a0plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE\u00a0randomized clinical trial","volume":"323","author":"Tap","year":"2020","journal-title":"J Am Med Assoc"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492100246X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492100246X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:22Z","timestamp":1760733082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492100246X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":43,"alternative-id":["S095980492100246X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG \u201cANITA\u201d","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}